OBP acting CEO suspended amid FMD vaccine pricing allegations

It is alleged that the company imported FMD vaccines at a lower cost but sold them at a higher price to farmers Onderstepoort Biological Products (OBP) Board has placed its acting CEO, Dr Jacob Modumo, on precautionary suspension as allegations surrounding the pricing of foot-and-mouth disease (FMD) vaccines come under scrutiny.

Acting CEO suspended “On Friday I convened an urgent meeting with the Board of OBP wherein I presented the Board with information on allegations of serious misconduct relating to the pricing of Foot and mouth disease (FMD) vaccines against the Acting CEO of OBP,” said Aucamp.“The Board, after considering the matter, gave the Acting CEO a notice of their intention to suspend him, and as per the OBP’s policy, has afforded him five days to provide reasons why he should not be suspended.”